Compare SFBC & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SFBC | VANI |
|---|---|---|
| Founded | 1953 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.8M | 100.0M |
| IPO Year | 2012 | 2014 |
| Metric | SFBC | VANI |
|---|---|---|
| Price | $42.93 | $1.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.50 |
| AVG Volume (30 Days) | 4.4K | ★ 149.2K |
| Earning Date | 04-28-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.04% | N/A |
| EPS Growth | ★ 53.89 | N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | N/A | ★ $4,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $70.48 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $40.68 | $0.92 |
| 52 Week High | $48.85 | $1.92 |
| Indicator | SFBC | VANI |
|---|---|---|
| Relative Strength Index (RSI) | 54.10 | 50.46 |
| Support Level | $41.29 | $1.17 |
| Resistance Level | $44.38 | $1.26 |
| Average True Range (ATR) | 1.11 | 0.06 |
| MACD | 0.11 | -0.00 |
| Stochastic Oscillator | 59.66 | 42.86 |
Sound Financial Bancorp Inc operates as the holding company for Sound Community Bank that provides traditional banking and other financial services for individuals and businesses. It attracts retail and commercial deposits from the public and invests those funds, along with borrowed funds, in loans secured by first and second mortgages on one-to-four-family residences including home equity loans and lines of credit, commercial and multifamily real estate, construction and land, consumer and commercial business loans. The bank also offers secured and unsecured consumer loan products, including manufactured home loans, floating home loans, automobile loans, boat loans, and recreational vehicle loans.
Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.